# Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

> **NCT02277184** · PHASE1 · TERMINATED · sponsor: **Julie E. Bauman, MD, MPH** · enrollment: 1 (actual)

## Conditions studied

- Carcinoma, Squamous Cell of Head and Neck

## Interventions

- **DRUG:** Ficlatuzumab
- **DRUG:** Cisplatin
- **RADIATION:** Intensity Modulated Radiotherapy (IMRT)

## Key facts

- **NCT ID:** NCT02277184
- **Lead sponsor:** Julie E. Bauman, MD, MPH
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** the investigator left the institution
- **Last updated:** 2017-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02277184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02277184, "Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02277184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*